Danmarks Nationalbank
OPENING OF NEW 10-YEAR BENCHMARK BOND ON 5 FEBRUARY 2025
OPENING OF NEW 10-YEAR BENCHMARK BOND ON 5 FEBRUARY 2025
On 5 February 2025, the Kingdom of Denmark will issue a new DGB 2.25 per cent 2035 (ISIN: DK0009924961) via auction. Coupons will be paid annually on 15 November and maturity will be on 15 November 2035. The new bond will replace DGB 2.25 per cent 2033 as key on-the-run issue. After this the central government can conduct buy-backs in DGB 2.25 per cent 2033.
The sale will commence via MTS Denmark's auction system with primary dealers as counterparts. The opening is contingent on stable market conditions. At the auction, the total sale will not exceed DKK 6 billion at nominal value.
As from 8:00 a.m. (CET) on the opening day, bids can be submitted until 10:15 a.m. Subsequently, a cut-off price will be fixed as quickly as possible and within 10 minutes at the latest. Bids at the cut-off price or above will be accommodated at the cut-off price. A pro-rata allocation of bids at the cut-off price may be applied.
Terms of borrowing can be viewed on www.governmentdebt.dk under Terms of borrowing.
SECURITIES LENDING
DGB 2.25 per cent 2035 will be included in the central government's securities lending facility from 5 February 2025.
FURTHER INFORMATION
For further information please contact the Danish debt management office at governmentdebt@nationalbanken.dk.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom